Dr. Vanderslice has spent over 20 years leading teams focused on the development of small molecule compounds that bind and modulate the function of integrins and chemokine receptors. The majority of his professional career has been in the pharmaceutical industry, where he gained familiarity with each stage of the pipeline from discovery to progression into clinical trials. Dr. Vanderslice has led teams working on several pre-clinical programs involving efforts in drug screening, lead compound characterization, and the development of preclinical animal models.See Publications
Texas Heart Institute Positions
- Director MCRL Biology, Molecular Cardiology Research
- Non-invasive diagnostic imaging technologies
University of Maryland
University of Texas at Austin (PhD)
University of California San Francisco
Honors, Awards and Memberships
- Parker B. Francis Fellowship in Pulmonary Research, University of California, San Francisco, CA
- Texas Heart Institute Professional Staff
Cell adhesion research could lead to a new pain alternative for patients with inflammatory conditions
Today more than 30 million patients suffer from painful inflammatory conditions. Prescription opioid pain relievers are commonly prescribed for these...
Grant from the NIH NIDDK to Advance Collaboration to Develop Treatments for Inflammatory Disease HOUSTON, TX, November 10, 2020 –...
Technology co-invented by scientists at the Texas Heart Institute and 7 Hills Pharma received broad patent protection from the U.S....